Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP22 | Q9NRW4 | 6/20 | 0.77 |
| ▸ | DUSP26 | Q9BV47 | 2/20 | 0.77 |
| ▸ | CFTR | P13569 | 3/20 | 0.63 |
| ▸ | BCL2 | P10415 | 3/20 | 0.61 |
| ▸ | IKBKB | O14920 | 2/20 | 0.59 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.59 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.59 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.59 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18102926 | 1.00 | DUSP22 (0.77) | DUSP22DUSP26CFTRBCL2IKBKB | |
| SCHEMBL18103078 | 0.92 | DUSP22 (0.80) | DUSP22DUSP26CFTRBCL2PTPN7 | |
| SCHEMBL20006090 | 0.92 | DUSP22 (0.80) | DUSP22DUSP26CFTRBCL2PTPN7 | |
| SCHEMBL24217824 | 0.84 | DUSP22 (1.00) | DUSP22DUSP26CFTRAMY1AMEN1 | |
| SCHEMBL24217784 | 0.82 | DUSP22 (1.00) | DUSP22DUSP26CFTRAMY1AMEN1 | |
| SCHEMBL27921909 | 0.82 | DUSP22 (1.00) | DUSP22DUSP26CFTRAMY1AMEN1 | |
| SCHEMBL18103087 | 0.81 | DUSP26 (0.74) | DUSP22DUSP26CFTRPTPN7PTPN12 | |
| SCHEMBL17762590 | 0.79 | DUSP22 (1.00) | DUSP22DUSP26CFTRBCL2AMY1A | |
| SCHEMBL1877096 | 0.78 | CFTR (1.00) | DUSP22DUSP26CFTRAMY1AMEN1 | |
| SCHEMBL1877094 | 0.78 | CFTR (1.00) | DUSP22DUSP26CFTRAMY1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | DUSP22 1957/4885DUSP26 2207/4885CFTR 2730/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | DUSP22 1957/4885DUSP26 2207/4885CFTR 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.